Highlights BioArctic AB

Equities

BIOA B

SE0010323311

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 09:30:00 09/07/2025 pm IST			5-day change	1st Jan Change
182.20 ^SEK	-1.41%		-0.98%	-8.67%

17/06	Lannebo Sverige Plus increased by 4.3 percent in May – rising profitability at Elekta	FW
13/06	BioArctic to Advance Parkinson's Disease Drug Trial After Positive Safety Review	MT

Highlights

BioArctic to Initiate Next Cohorts in Exidavnemab Phase 2a Study After Positive Safety Review	13/06	CI
EU Committee Backs BioArctic's Exidavnemab for Multiple System Atrophy in EU	22/05	MT
Bioarctic Receives Positive Opinion For Orphan Medicinal Product Designation In EU	22/05	RE
Bioarctic AB Announces That the European Medicines Agency Committee for Orphan Medicinal Products Recommends Orphan Medicinal Product Designation to Exidavnemab for the Treatment of Multiple System Atrophy	22/05	CI
BioArctic AB Reports Earnings Results for the First Quarter Ended March 31, 2025	21/05	CI
Eisai Projects Leqembi® Revenue To Total JPY 76.5 Billion For FY 2025	15/05	RE
BioArctic Secures Regulatory Nod to Expand Parkinson's Disease Therapy's Mid-stage Study	08/05	MT
Bioarctic AB Announces Regulatory Authorities in Spain in Poland Approves the Inclusion of Multiple System Atrophy Patients for Treatment with the Alpha-Synuclein Antibody Exidavnemab in the Ongoing Exist Phase 2A Study	08/05	CI
BioArctic Gets European Patent for Synucleinopathies Drug Candidate	23/04	MT
BioArctic's Partner Eisai Secures EU Commission's Approval for Alzheimer's Disease Drug	16/04	MT
BioArctic Says EU Commission to Make Final Decision on Alzheimer's Disease Drug	14/04	MT
BioArctic AB Presents Data on Exidavnemab and Lecanemab at 2025 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders	07/04	CI
EU Appeal Committee to Review Eisai-BioArctic's Alzheimer's Disease Drug	01/04	MT
BioArctic AB and Eisai to Present Data on Real-World Use of Lecanemab at the 2025 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders	27/03	CI
Bioarctic Says Eisai Simulates Leqembi Sales To Reach JPY 250-280 Bln In FY 2027	25/03	RE
US FDA Grants Orphan Drug Designation for BioArctic's Multiple System Atrophy Drug	18/03	MT
EU Panel Reconfirms Recommendation for BioArctic Partner's Alzheimer's Drug	28/02	MT
BioArctic-Bristol Myers Squibb Alzheimer's Deal Clears US Regulatory Hurdle	20/02	MT
Bioarctic's Global License Agreement with Bristol Myers Squibb for Pyroglutamate-Amyloid-Beta Antibody Program Effective After Antitrust Clearance and Closing	20/02	CI
BioArctic AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	13/02	CI
Pareto's Swedish portfolio underperformed in January, replaces half of holdings (R)	03/02	FW
EU Commission Asks CHMP to Review More Information in BioArctic Partner's Alzheimer's Disease Drug Approval	31/01	MT
Carnegie raises target price for Bioarctic to SEK 350 (318), reiterates Buy - BN	28/01	FW
BioArctic's Partner Obtains Supplemental License for Leqembi from US FDA	27/01	MT
US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug	27/01	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BioArctic AB

Equities

BIOA B

SE0010323311

Biotechnology & Medical Research

Highlights

Filters